Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
EGFR Inhibitors Benefit Metastatic CRC Patients
Cochrane; 2017 Jun 27; Chan, et al
Epidermal growth factor receptor monoclonal antibody (EGFR Mab) drugs reduce disease progression and improve survival in patients with metastatic colorectal cancer, according to a recent review of the evidence published by the Cochrane Library. Details of the analysis include the following:
- When used in combination with standard treatment, EGFR Mabs are effective in patients whose tumors are KRAS wide type, ie, those that do not have mutations in the KRAS gene.
- KRAS wide type patients experience a 30% reduction in the risk of disease progression and a 12% reduced risk of death.
- EGFR tyrosine kinase inhibitors, which include agents such as erlotinib and gefitinib, do not improve clinical outcomes in patients with metastatic colorectal cancer.
Chan DLH, Segelov E, Wong RSH, et al. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. Cochrane Database of Systematic Reviews. 2017, Issue 6. Art. No.: CD007047. doi:10.1002/14651858.CD007047.pub2.
This Week's Must Reads
Must Reads in Clinical Guidelines
AGA Guideline: Drug Monitoring in IBD, Gastroenterology; 2017 Sep; Feuerstein, et al
AGA Clinical Practice Update: Per-Oral Endoscopic Myotomy for Achalasia, Gastroenterology; 2017 Nov; Kahrilas, et al
AGA Clinical Practice Update: Tx for Fecal Incontinence, Clin Gastroenterol Hepatol; 2017 Dec; Bharucha, et al
ACG/CAG Updates Guidelines on Dyspepsia, Am J Gastroenterol; ePub 2017 Jun 20; Moayyedi, et al
EGFR Inhibitors Benefit Metastatic CRC Patients, Cochrane; 2017 Jun 27; Chan, et al